Ascendis Pharma A/S (NASDAQ: ASND) announced results from a 5-year Phase 2 trial showing sustained efficacy and safety of TransCon ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE